Xcell Therapeutics Inc. (KOSDAQ:373110)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,770.00
-100.00 (-2.58%)
Apr 28, 2025, 12:40 PM KST
-69.79%
Market Cap 42.33B
Revenue (ttm) 1.93B
Net Income (ttm) -9.54B
Shares Out 10.94M
EPS (ttm) -954.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,029
Average Volume 285,563
Open 3,885.00
Previous Close 3,870.00
Day's Range 3,750.00 - 3,885.00
52-Week Range 3,220.00 - 12,900.00
Beta n/a
RSI 44.14
Earnings Date May 15, 2025

About Xcell Therapeutics

Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 373110
Full Company Profile

Financial Performance

In 2024, Xcell Therapeutics's revenue was 1.93 billion, an increase of 72.11% compared to the previous year's 1.12 billion. Losses were -9.54 billion, 2.83% more than in 2023.

Financial Statements

News

There is no news available yet.